Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
Seattle Institute for Biomedical and Clinical Research
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2625
- sponsor
- Seattle Institute for Biomedical and Clinical Research
- conditions
- Alzheimer Disease
- interventions
- DRUG: Naproxen Sodium (Aleve); DRUG: Celecoxib (Celebrex)
- start date
- 2001-01-01
- primary completion date
- 2007-05-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT00007189
- Published
- Dec 14, 2000
- Updated
- Oct 19, 2016
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT00007189
- Categories
- Alzheimer Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials